| |
Figure 3. Analysis of the FoxN3 small eye phenotype. Thirteen nanograms of FoxN3-MO were co-injected with 200 pg GFP RNA in one blastomere at 2-cell stage. Asterisks denote the injected side. A,B: Whole mount in situ hybridization of unilaterally FoxN3-MO-injected embryos showing xRx staining in the eye field. A: Frontal view of a stage-16 embryo. B: Dorsal view of a stage-30 embryo. The insert shows a magnification of the right and left eye. No difference in xRx expression between injected and uninjected side is noted. C,C': Comparison of the injected (FoxN3-MO) and uninjected side of an embryo at stage 35. C' shows the injected side. No difference in the size of the forming eyes is observed. D,D': Right and left view of an unilaterally injected embryo, stage 39. D' shows the injected side. The eye at the FoxN3-MO injected side is clearly reduced in comparison to the uninjected side. E, F: Sections of Alcian blue-stained eyes of the uninjected control side (E) and the FoxN3-MO-injected side (F) of an embryo at stage 48. F: The eye is smaller but shows a normal structure. The different layers of the retina are clearly visible indicating that the differentiation of the retina is not affected by FoxN3-MO injection. The black arrows denote the optic nerve, indicating identical planes of section in E and F. |
